"The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternat"...
Lusedra Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Lusedra (fospropofol disodium injection) is a sedative-hypnotic agent used for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures. The brand name of this medication is discontinued, but generic versions may be available. Common side effects include itching, or a sensation of burning, tingling, or stinging.
In adults aged 18 to 65 years who are healthy or have mild systemic disease, the standard dosing regimen of Lusedra is an initial intravenous bolus of 6.5 mg/kg followed by supplemental doses of 1.6 mg/kg intravenously (25% of initial dosage) as needed to achieve the desired level of sedation. Lusedra may interact with other sedative-hypnotics, or narcotics. Tell your doctor all medications and supplements you use. During pregnancy, Lusedra should be used only if prescribed. It is unknown if this drug passes into breast milk; however, similar drugs have been reported to pass into breast milk, and the effects of oral absorption of this drug are unknown. Lusedra is not recommended for use in nursing mothers. Withdrawal symptoms may occur if you suddenly stop taking this medication.
Our Lusedra (fospropofol disodium injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Lusedra FDA Prescribing Information: Side Effects
The following serious adverse reactions are discussed elsewhere in the labeling:
- Respiratory depression [see WARNINGS AND PRECAUTIONS]
- Hypoxemia [see WARNINGS AND PRECAUTIONS]
- Loss of purposeful responsiveness [see WARNINGS AND PRECAUTIONS]
- Hypotension [see WARNINGS AND PRECAUTIONS]
The most common adverse reactions (reported in greater than 20%) are paresthesia and pruritus. The most commonly reported reasons for discontinuation are paresthesia and cough.
Clinical Trials Experience
Adverse reactions presented in this section are derived from 332 patients in 3 controlled clinical trials in patients undergoing colonoscopy or flexible bronchoscopy and 123 patients in one open-label study in patients undergoing minor procedures. Patients enrolled in the studies who received the standard or modified dosing regimen included males and females, ≥ 18 years of age and ranging from healthy (359/455 [79%] ASA P1 or P2) to those with severe systemic disease (96/455 [21%] ASA P3 or P4). Of the 455 patients enrolled, 345 (76%) were ≥ 18 to < 65 years of age and 110 (24%) were ≥ 65 years of age. Adverse reactions are reported for patients who received the standard or the modified dosing regimen [see DOSAGE AND ADMINISTRATION]. The majority of procedures were less than thirty minutes in duration. All patients in these studies received 50 mcg fentanyl citrate intravenously as premedication, and some of the patients received additional 25 mcg fentanyl citrate supplemental doses. Adverse reactions occurring in ≥ 2% of patients in these studies are presented in Table 3.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not accurately reflect the rates observed in practice.
Table 3. Common Adverse Reactions for Patients Receiving
the Standard or Modified Dosing Regimen (Reactions Occurring at a Rate ≥ 2%)
|Reaction Term|| Colonoscopy
| Minor Procedures
|Injury, poisoning, and procedural complications|
|Nervous system disorders|
|Paresthesiaa||135(74)||77 (63)||78 (52)|
|Respiratory, thoracic, and mediastinal disorders|
|Skin and subcutaneous tissue disorders|
|a Paresthesia includes the following terms: Paresthesia genital male; Burning sensation; Genital burning sensation; Vaginal burning
sensation; Skin burning sensation; Genital pain (reported as burning); Perineal
pain (reported as burning); Anal discomfort (reported as burning); Chest
pain (reported as burning); Ear discomfort (reported as burning); Nasal
discomfort (reported as burning); Buttock pain (reported as stinging); Groin
pain (reported as stinging); Pain (reported as stinging); Sensory disturbance
(reported as non-specific sensation in pubic area).
b Pruritus includes the following terms: Genital pruritus female; Genital pruritus male; Pruritus genital; Pruritus ani; Pruritus generalized.
Paresthesias (including burning, tingling, stinging) and/or pruritus, usually manifested in the perineal region, were the most frequently recorded adverse reactions in clinical trials. Paresthesias and pruritus generally occurred within 5 minutes after administration of the initial dose of LUSEDRA (fospropofol disodium injection) and were generally transient and mild to moderate in intensity. The pharmacologic basis of these sensory phenomena is unknown. No pretreatments, including the use of nonsteroidal anti-inflammatory drugs, opioids, or lidocaine, are known to have an effect on or to reduce the incidence of these sensations.
Sedation-related adverse reactions were experienced at the following rates for subjects receiving the standard or modified LUSEDRA (fospropofol disodium injection) dosing regimen: 20/455 (4%) hypoxemia, 18/455 (4%) hypotension, 1/455 ( < 1%) apnea. A greater rate of sedation-related adverse reactions necessitating intervention was observed in patients undergoing bronchoscopy compared with colonoscopy and minor surgical procedures. In the colonoscopy studies, 5/183 (3%) patients were ASA P3. In the minor surgical procedures study, 23/123 (19%) patients were ASA P3 or P4. In the flexible bronchoscopy study, 68/150 (46%) patients were ASA P3 or P4. The type and incidence of airway assistance interventions required for patients who experienced sedation-related adverse reactions are presented in Table 4.
Table 4. Patient Incidence of Airway Management Events
| Healthy Subjectsa |
| Colonoscopyb |
6.5 mg/kg (or modified dosing regimen)
| Minor Proceduresb |
6.5 mg/kg (or modified dosing regimen)
| Flexible Bronchoscopyb
6.5 mg/kg (or modified dosing regimen)
|Increased O2||0||0||0||21 (14)|
|Verbal Stimulation||0||2(1)||1 (1)||5(3)|
|Face Mask (100% O2)||0||0||0||1 (1)|
|Chin Lift||0||0||1 (1)||3(2)|
|Manual Ventilation (bag valve mask)||0||0||0||1 (1)|
|a No concomitant medications administered. All
subjects were healthy volunteers.
b All patients premedicated with 50 mcg fentanyl citrate. Subjects ranged from healthy to those with severe systemic disease that is a constant threat to life (ASA P1 to P4).
Adverse Reactions in Prolonged Exposure in Adults
The safety of LUSEDRA (fospropofol disodium injection) for continuous sedation has not been established and therefore its use is not recommended. LUSEDRA (fospropofol disodium injection) was administered to 38 intubated and mechanically ventilated patients in postoperative and intensive care settings. An occurrence of nonsustained ventricular tachycardia was observed as a serious adverse reaction in one patient in the study. Another patient with acute myeloid leukemia with renal and hepatic insufficiency experienced a further increase in plasma formate concentration from a baseline of 66 mcg/mL to a post-dose level of 212 mcg/mL after a 12-hour infusion. The clinical significance of these findings is unknown.
Read the entire FDA prescribing information for Lusedra (Fospropofol Disodium Injection)
Additional Lusedra Information
- Lusedra Drug Interactions Center: fospropofol iv
- Lusedra Side Effects Center
- Lusedra FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Chronic Pain/Back Pain
Find tips and advances in treatment.